By Adriano Marchese
Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents.
The U.S. District Court of Massachusetts ruled that Pfizer's motion that U.S. Patent Number 11,358,953 is invalid, Enanta said Tuesday.
Through a patent infringement lawsuit, the clinical-stage biotechnology was seeking damages for infringement of the patent in the manufacture, use and sale of Pfizer's Paxlovid.
The court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity.
"Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit," it said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 24, 2024 07:24 ET (12:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。